

Where will we LEAP next?



On September 9, 2024 LEAP and CELT convened approximately 50 in-person and 120 virtual registrants for a one-day workshop intended to catalyze coordinated activity to streamline development and approval of generic LAI ARV products. Opening remarks from CELT, DAIDS, and LEAP leadership were followed by four Plenary Sessions and two Open Discussions. Presenters represent diverse perspectives, including: Regulatory, formulation, manufacturing, and intellectual property experts; Investigators; Clinicians; Funders; and Community advocacy groups. Topics were strategically selected to help collectively identify novel, more efficient approaches to bioequivalence assessment of low-cost generic LAI ARV products and improve access to life-saving treatments among populations and geographies with the greatest need. This report summarizes plenary session presentations and major themes from the open discussions.



Andrew Owen Co-director, Centre of Excellence for Long-acting Therapeutics (CELT)

“Funders have been catalytic in long-acting medicine development for HIV and other diseases”

Dr. Owen welcomed workshop participants to Liverpool on behalf of CELT and CELT Co-director, Steve Renard. He thanked attendees of the previous days' workshops on drug-drug interactions and antiviral pharmacology. Dr Owen expressed particular gratitude to UNITAID for the establishment of CELT and the LONGEVITY grant and to the NIH for the establishment of LEAP and other investments in the LA space.